Pharma Packaging Solutions

JUNE 30, 2023

Hormones (such as insulin, glucagon, and growth hormone, to name a few) are produced by recombinant DNA, as are blood factors, thrombolytic agents, interferons, monoclonal antibodies, therapeutic enzymes, and more.

Recombinant DNA Technology 52

Recombinant DNA Technology Packaging Packaging Gene Therapy 52

XTalks

JUNE 20, 2022

Hereditary ATTR has an autosomal dominant pattern of inheritance and is caused by point mutations in the transthyretin ( TTR ) gene that codes for the transthyretin transport protein found in the plasma and cerebrospinal fluid.

FDA Approval 98

FDA Approval Protein Genetics RNA 98

pharmaphorum

AUGUST 16, 2022

AstraZeneca and Merck & Co’s PARP inhibitor Lynparza is already used to treat prostate cancer associated with a specific genetic mutation, but could see its use broadened if a new marketing application is approved by the FDA. months and 16.6 months, respectively.

Hormones 111

Hormones Gene Sales Trials 111

Drug Discovery Today

FEBRUARY 13, 2020

Experts in the emotional needs of small children say increased levels of the stress hormone cortisol in babies and small children who are separated from their parents, especially their mothers, could have a long-term genetic impact on future generations.

Hormones 40

Hormones Gene Genetics Medicine 40

Drug Discovery World

APRIL 6, 2023

Olaparib is PARP inhibitor that targets cancers linked to faulty BRCA1 or BRCA2 genes and works across many different cancer types. Men in England and Wales with advanced, incurable prostate cancer who have BRCA1/2 mutations in their tumours and who have seen their cancer progress despite hormone therapy will also have access to olaparib.

Hormones 52

Hormones Gene Scientist Clinical Trials 52

XTalks

MARCH 13, 2024

Hormone-based therapeutics aim to delay glaucoma progression by enhancing estrogen’s potential protective effects. There are also studies examining gene therapy-based techniques to repair or replace genetic defects contributing to this disease.

Gene Therapy 111

Gene Therapy Gene Life Science DNA 111

pharmaphorum

JANUARY 16, 2023

Hormone replacement therapy (HRT) could cut the risk of Alzheimer’s in some women at elevated risk of the disease, according to researchers in the UK.

Hormones 75

Hormones Genotype Research Genetics 75

The Pharma Data

NOVEMBER 24, 2020

25, 2020 /CNW/ – On August 21, 2020 , Health Canada approved Lynparza® (olaparib), for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA or ATM- mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with a new hormonal agent (NHA).

Gene 52

Gene Hormones DNA Medicine 52

pharmaphorum

SEPTEMBER 24, 2021

AstraZeneca and Merck & Co PARP inhibitor Lynparza is already used to treat prostate cancer associated with a specific genetic mutation, but could see the drug’s use broadened after a positive phase 3 trial.

Hormones 52

Hormones Genetics Sales Drugs 52

Scienmag

MARCH 11, 2021

During pregnancy, the hormone progesterone helps to […]. The study in mice — published online in the Proceedings of the National Academy of Sciences — provides novel insights for developing treatments.

Hormones 74

Hormones Development Research Gene 74

The Pharma Data

SEPTEMBER 3, 2020

Comparing four separate forms of the disease, they found that samples of the most aggressive form, known as metastases-like primary tumours, saw changes in activity of 74 immune-related genes, compared with changes in only 12 in the more benign insulinoma-like tumours.

Research 52

Research Genetic Analysis Gene Scientist 52

Scienmag

DECEMBER 7, 2020

University of Pennsylvania biologists have uncovered one way plants respond to hormonal cues. A similar process is likely at play in mammals. Just like other organisms, plants must respond dynamically to a variety of cues over their lifetime.

Hormones 63

Hormones Gene Genetics Medicine 63

XTalks

SEPTEMBER 17, 2020

Symptoms and Etiology: Caused by an overproduction of growth hormone, acromegaly primarily affects adults. By reducing the amount of growth hormone in the blood, progressive enlargement of bones should be slowed. By reducing the amount of growth hormone in the blood, progressive enlargement of bones should be slowed.

Trials 98

Trials Gene Hormones Clinical Trials 98

Drug Discovery World

APRIL 4, 2023

Read more: FDA Fast Track Designation for retinitis pigmentosa treatment Drug candidate for TUBB4a leukodystrophy, SynaptixBio The FDA has granted Rare Paediatric Disease (RPD) Designation to SynaptixBio’s drug candidate for TUBB4a leukodystrophy – a genetic and debilitating condition which mainly affects babies and young children.

FDA Approval 52

FDA Approval In-Vivo Gene Editing Drugs 52

The Pharma Data

NOVEMBER 21, 2021

Achondroplasia is a genetic condition that causes severely short stature and disproportionate growth. People with achondroplasia have a genetic mutation that causes a certain growth regulation gene called fibroblast growth factor receptor 3 to be overly active, which prevents normal bone growth.

FDA Approval 52

FDA Approval Drugs Regulation Genetics 52

XTalks

AUGUST 15, 2023

Akeega is a dual-action tablet (DAT) that contains the company’s androgen receptor-targeting hormone therapy Zytiga (abiraterone acetate) and PARP inhibitor (poly [ADP-ribose] polymerase inhibitor) niraparib. Lynparza received FDA approval in May 2020 for mCRPC in patients with homologous recombinational repair ( HRR ) gene mutations.

FDA Approval 52

FDA Approval Gene Hormones Licensing 52

Roots Analysis

AUGUST 31, 2023

Overview of Gene Switch The notion that genes might be turned on and off was discovered several decades ago when studies revealed that E. Gene switches are sites on genes where regulatory molecules can bind to trigger transcription process, leading to expression of a particular gene.

Gene 40

Gene Gene Therapy Gene Expression Regulation 40

Delveinsight

JULY 30, 2020

Adrenoleukodystrophy (ALD/ X-ALD) is a rare, X-linked disorder secondary to a mutation in the ABCD1 gene, which encodes for a peroxisomal membrane protein, resulting in an excessive accumulation of very-long-chain fatty acids (VLCFAs) in the brain and adrenal glands. The disorder can occur at any stage of life and vary with severity.

Hormones 52

Hormones Marketing Gene Trials 52

The Pharma Data

OCTOBER 15, 2020

Also, family history is key since the same genes that can raise breast cancer risks in women — BRCA1 and BRCA2 — work similarly in men. This seems consistent with what we know about hormonal changes in this group of individuals.” And Police added that there’s one subgroup who might face special risks.

Genetics 52

Genetics Hormones Research Gene 52

The Pharma Data

AUGUST 15, 2021

target genes associated with cellular proliferation, angiogenesis and tumor growth. Advise patients of these risks and the need for effective non-hormonal contraception. WELIREG can render some hormonal contraceptives ineffective. Advise patients of these risks and the need for effective non-hormonal contraception.

Hormones 52

Hormones Clinical Trials Clinical Trials Trials 52

The Pharma Data

JUNE 2, 2023

This approval reinforces the importance of routine testing for genetic mutations at metastatic diagnosis to help guide clinical decisions.” In PROpel, the LYNPARZA combination improved rPFS and OS for the subgroup of patients with BRCA m mCRPC. In the U.S., These approvals were based on the data from the Phase 3 PROfound trial.

FDA Approval 52

FDA Approval HR Trials Hormones 52

The Pharma Data

JANUARY 7, 2021

To meet that goal, Sanofi is investing in areas like synthetic biology and cell and gene therapy. Another area where Sanofi is investing is through the Expanded Genetic Alphabet platform it gained at the end of 2019 through the $2.5 billion acquisition of Synthorx.

Protein 52

Protein Antibody Genetics Gene Therapy 52

pharmaphorum

DECEMBER 23, 2020

2020 also saw some of the first “tumour agnostic” cancer drugs get to market, with Bayer’s Vitravki (larotrectinib) getting funding in the UK for tumours with confirmed neurotrophic tyrosine receptor kinase (NTRK) gene fusions.”. Pharma companies have also made headway in rare diseases as several pipeline projects came to fruition.

Marketing 97

Marketing Gene Silencing Gene Drugs 97

Delveinsight

AUGUST 6, 2020

Transthyretin (TTR) is a protein that the liver produces to facilitate the transfer of thyroid hormone and vitamin A in the blood. Hereditary ATTR amyloidosis , also known as Familial ATTR, is an autosomal dominant disease and a result of mutations in the TTR gene, thus it is passed down from one generation to the next one.

Gene Silencing 52

Gene Silencing Protein Marketing Gene 52

pharmaphorum

JULY 28, 2022

Alnylam Pharma has made a name for itself, developing gene-silencing therapies for rare disorders, but its latest discovery could take it into a much larger category – metabolic and cardiovascular disease. Transgenic mice in which the gene has been deleted have improved control of blood glucose and insulin sensitivity.

Biobanking 52

Biobanking Gene Gene Silencing Drugs 52

XTalks

MARCH 22, 2021

Using a simple, standard blood sample, the assay can detect actionable genetic mutations in cancers, including cancer-driving alterations. The tool analyzes the differential expression of over 90 genes to distinguish between 50 tumors types and subtypes. Both of Biotheranostics’ diagnostics are PCR-based gene expression tests.

Life Science 110

Life Science Development Marketing Gene Expression 110

The Pharma Data

JUNE 24, 2021

“The prognosis for men with advanced prostate cancer has significantly improved since the introduction of novel hormone therapies, but additional therapeutic options are needed for the approximately 25 percent of men with tumors harboring DNA damage response (DDR) gene mutations, who may have poorer outcomes,” said Chris Boshoff, M.D.,

DNA 52

DNA Clinical Trials Clinical Trials Trials 52

XTalks

MARCH 7, 2024

Optimizing Sleep During Perimenopause and Beyond Sleep plays a crucial role in overall health, particularly for midlife women transitioning into menopause, a phase marked by perimenopause where hormonal changes can severely disrupt sleep due to symptoms like nocturnal hot flashes.

Hormones 115

Hormones Genetics Genome Genomics 115

The Pharma Data

DECEMBER 9, 2020

The Chinese biopharmaceutical industry is growing in leaps and bounds, but there is still a huge unmet need when it comes to getting patients access to the breakthrough therapeutic modalities and platforms like RNAi, cell and gene therapy and others. A solution could be at hand with Overland Pharmaceuticals.

In-Vivo 52

In-Vivo In-Vitro Antibody Development 52

XTalks

MAY 17, 2023

While the exact physiology of vasomotor symptoms is not fully understood, it is believed that the significant fluctuations in reproductive hormones play a role in triggering these symptoms. Hormone replacement therapy is thought to be one of the most effective treatments for vasomotor symptoms.

Hormones 95

Hormones FDA Approval Drugs Clinical Trials 95

XTalks

NOVEMBER 20, 2023

AstraZeneca has won its first-in-class approval for its AKT inhibitor Truqap (capivasertib) in combination with Faslodex (fulvestrant) for treating patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer.

HR 98

HR FDA Approval Gene Trials 98

Drug Discovery World

FEBRUARY 20, 2023

Novartis’ Lutetium-177 PSMA-617 is limited to cases carrying the surface molecule PSMA (prostate specific membrane antigen) and in patients who had previously received chemotherapy and who do not respond to hormone withdrawal.

Drug Trials 52

Drug Trials Trials Clinical Trials Clinical Trials 52

XTalks

FEBRUARY 5, 2024

Alecensa is approved in Japan for the additional indication of recurrent or refractory ALK fusion gene-positive anaplastic large-cell lymphoma. Zoladex is an artificial form of a hormone that regulates many processes in the body. Alecensa is not currently available in generic form. mg implant) is around $1,006.

FDA Approval 101

FDA Approval Drugs Sales Development 101

Delveinsight

JANUARY 13, 2021

An Individual’s metabolic activity, genetics, environmental factors, behavior, and hormones can supposedly cause overweight and obesity. Apart from calorie and physical activity, some of the genetic and social factors also influence the prevalence of obesity. What causes obesity? What are the risk factors for obesity?

Hormones 52

Hormones Gene Genetics Production 52

Delveinsight

DECEMBER 2, 2020

Some of the most common factors include: Genes – Genes are considered to play a small role in Rheumatoid Arthritis. Smoking – Cigarette smoking, coupled with the genetic factor, can increase the risk of developing Rheumatoid Arthritis. However, the role of hormones is still unclear.

Marketing 60

Marketing Hormones Antibody Development 60

The Pharma Data

JANUARY 21, 2021

They found an unusual result—the most frequently mutated ALS genes found in general populations were typically not affected in Malta ALS patients. Specifically, the Malta patients did not have mutations in the C9orf72, SOD1, TARDBP and FUS genes. It also reversed age-related mental decline in older mice.

Research 52

Research DNA Hormones Vaccination 52

XTalks

FEBRUARY 5, 2024

Alecensa is approved in Japan for the additional indication of recurrent or refractory ALK fusion gene-positive anaplastic large-cell lymphoma. Zoladex is an artificial form of a hormone that regulates many processes in the body. Alecensa is not currently available in generic form. mg implant) is around $1,006.

FDA Approval 52

FDA Approval Drugs Sales Development 52